Profusa, Inc.

Profusa, Inc., trading under the ticker PFSA, is a health technology company focused on implantable biosensor systems designed to enable continuous, real-time monitoring of key physiological biomarkers including glucose and oxygen. The company filed a definitive proxy statement (DEF 14A) with the SEC on August 28, 2026, accession number 0001213900-26-095087, indicating shareholders are being asked to vote on a significant corporate action in connection with a SPAC business combination. Profusa operates in the medical devices and digital health sector, with its tissue-integrating sensor platform developed in part through federal research partnerships. Visit SpacDesk and sign up for full data, filings, and analytics on PFSA and every active SPAC transaction.